Trial Profile
A Single Centre, Randomized, Double-blind, Dose Ascending, Placebo-controlled Study, in Two Parts, to Evaluate the Safety, Tolerability and Pharmacokinetics of Escalating Single and Repeat Inhaled Doses of GSK573719 and Placebo Formulated With the Excipient Magnesium Stearate, in Healthy Subjects and in a Healthy Population of Cytochrome P450 Isoenzyme 2D6 Poor Metabolisers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Sep 2023
Price :
$35
*
At a glance
- Drugs Umeclidinium (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 20 May 2012 Results reported at the 108th International Conference of the American Thoracic Society.
- 09 Dec 2008 New trial record.